In a study of 1537 AML patients treated intensively within protocols of the AMLSG study group, we were able to demonstrate that even TP53 VAFs of less than 20% represent significant adverse risk factors for both OS and event-free survival [26]. Here, TP53 is linked to acute myeloid leukemia.